



IFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Chikara MURAKATA et al. **Confirmation No.: 6880**Serial No : 10/575,093 **Group Art Unit: 1614**

(National Stage of PCT/JP2004/015293)

I.A. Filed : October 8, 2004 **Examiner: not yet assigned**

For : THIADIAZOLINE DERIVATIVE

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner of Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Further to the Information Disclosure Statements filed December 15, 2006, and April 10, 2007, and in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants bring the following documents to the attention of the Examiner, which were cited the Partial European Search Report with respect to corresponding European Application EP 04792510.2:

- (1) EP 0 207 004 A, December 12, 1986, including an English language abstract;
- (2) U.S. Patent No. 4,699,913 (Farooq et al.), October 13, 1987; Applicants note that this document is a family member of document (1);
- (3) D.M. Evans et al., Journal of the Chemical Society, Perkin Transactions 1, 1986, Vol. 8, pp. 1499-1505; and
- (4) K. Zelenin et al., Chemical Abstracts, 1982, Vol. 97, No. 19, p. 708, Abstract No. 162877w.

Copies of the above-listed documents (with exception of the U.S. patent), the Supplementary Partial European Search Report with respect to EP 04792510.2 are  
{P29760 00184919.DOC}


enclosed together with a completed copy of the PTO-1449 Form listing the above-noted documents. The Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Further to 37 C.F.R. §1.98 (a)(2)(ii) and to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if a U.S. patent application was filed after June 30, 2003, a copy of the U.S. patent is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there are any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,  
Chikara MURAKATA et al.

  
Bruce H. Bernstein  
Reg. No. 29,027

42,920

May 9, 2007  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

